Most Relevant Terms per Topic

Abstracts with Biological Entities (English) - 75 Topics / Sub-Topic Model 13

Topic 1 Topic 2 Topic 3 Topic 4 Topic 5 Topic 6 Topic 7 Topic 8 Topic 9 Topic 10 Topic 11 Topic 12 Topic 13 Topic 14 Topic 15
1 mice vaccines IBV L. mucosal vectors influenza vlps DNA VSV adjuvant MVA sars-cov RSV mers-cov
2 responses vaccine pigs TGEV intranasal vector H5N1 VLP dna vaccine niv HCV vaccinia SARS respiratory MERS
3 immune development PRRSV oral dendritic HIV-1 HA particles dna vaccines rvsv advax ZIKV acute syncytial middle
4 response diseases chickens lactis route adenovirus pandemic virus-like plasmid EBOV cpg smallpox coronavirus passive east
5 vaccine pathogens NDV casei systemic transgene viruses virus-like particles dna vaccination ebola formulated ankara acute respiratory syndrome calves RBD
6 antibody infectious vaccinated lactobacillus administration ad influenza vaccines plants HPV GP alum CHIKV sars-cov. neonatal middle east respiratory syndrome coronavirus
7 induced review virulent orally delivery MV hemagglutinin baculovirus electroporation stomatitis ™ dengue cov cotton domain
8 study safety bronchitis gastroenteritis iga measles influenza virus proteins plasmids vesicular inulin poxvirus spike tract mers-cov infection
9 antibodies infectious diseases challenged LAB lymph foreign NP plant injection SUDV subjects vaccinia virus sars-cov infection respiratory syncytial virus spike
10 protein animal shedding PEDV nasal adenoviral avian insect pestis cats rov-asp-1 virus severe rats coronavirus
11 protective effective virus salmonella routes gene influenza vaccine expression dna immunization ebola virus delta WNV syndrome respiratory tract camels
12 results systems PEDV transmissible cells gag H1N1 edible skin animals OVA VRP monkeys parainfluenza sars-cov-2
13 immunized recent infectious bronchitis virus diarrhea surfaces viral vectors tuberculosis transgenic HPV16 hamsters formulation zika i.p rsv f syndrome
14 cell strategies strain recombinant dendritic cells HIV m2e production L1 rabies TCI replicon goats passive immunity chadox1 mers
15 humoral human poultry l. lactis i.n tumor H7N9 recombinant proteins encoding felv aluminum SFTSV s-peptide ds-cav1 respiratory
16 immunization clinical S1 typhimurium nodes adenoviruses universal transgenic plants Y. rabies virus delta inulin EDIII sl-cov pups middle east respiratory syndrome
17 cellular approaches newcastle plantarum sublingual vaccine vector BCG vlp-based plague recombinant vesicular stomatitis virus MIV gn sars coronavirus born dromedary
18 high delivery PRRS mucosal parenteral pre-existing influenza viruses capsid L2 RABV patch gc cphv-1 infants receptor-binding
19 neutralizing immune reproductive oral vaccine mucosa evolution conserved expression systems gene malaria liposomes fever respiratory cattle subunit
20 infection adjuvants birds porcine nanoparticles adenoviral vectors virus plant-derived mrna vesicular stomatitis virus adjuvants VACV phe-cov palivizumab dromedary camels
21 immune responses potential inactivated lactococcus mucosal vaccination env heterologous insect cells IL-12 FIPV WIV modified vaccinia virus ankara sars-cov vaccine EV-D68 2012
22 elicited including porcine transmissible gastroenteritis virus mucosal immunity hiv-1 vaccine M1 produced turkeys virus biojector lc16m8 ferrets BHV-1 MNA
23 cells advantages rotavirus lactic dcs gp120 TB viral ID kittens ODN equine acute respiratory syndrome coronavirus gd COVID-19
24 specific application industry PED intranasally vaccine vectors M2 formation E6 ebolavirus MF59 chadox1 3a exposure mers-cov vaccines
25 showed antigens live S. DC antigens H5 nov plasmid dna % mg replication-deficient rrbd HPIV3 mers-cov vaccine
26 induce veterinary WCL piglets local phenotype subtype edible vaccines cervical outbreaks sc nabs leptospirosis gilts chadox1
27 levels trials IB oral administration tissues HSV-2 h5n1 viruses vlp-based vaccines papillomavirus RV conjugate VV sars-cov s protein virus mers-cov.
28 model field adjuvanted protein intestinal express HPAI structural pvax1 ad5 T7-EA chikungunya s protein dams rbd-specific
29 immunity research PRRS-MLV VP2 sites viral seasonal EV71 a.c.nps feline core niv-g vaccine immunisation receptor-binding domain
30 generated design challenge pylori draining insertion H3N2 expressed microneedles nipah polio vaccinia virus ankara inactivated HRV16 tpa
31 immunogenicity clinical trials sows l. casei immunization replication h5n1 virus recombinant needle rad shsp RVF re-emergence PIV5 rad/spike
32 vaccination technologies S2 coli vaccination ad-based H7 system lcrv plasmodium VRC mutant 2003 gp350 svlp
33 suggest important lung intestinal lymph nodes recombinant homologous sf9 dna delivery IL-18 MUC1 encephalitis eosinophilic hmpv DPP4
34 protection antigen control lactobacilli site genes 2009 assembly acherv-trihpv filovirus transcutaneous SFTS sars-coronavirus head-only hdpp4
35 effective years GP5 lactic acid bacteria intranasal route viruses lethal virions y. pestis glycoprotein ov-asp-1 CCHF sars-like antibodies rbd-based
36 recombinant immune system rndv lactobacillus casei dc-targeting measles virus H9N2 subunit delivered sporozoite pcmvcorekozak VTT pcdnasa pre-f ad5/mers
37 epitope efforts infectious igg oral gag-specific TIV virus-like particle cervical cancer nipah virus adverse events smallpox vaccine syndrome-associated b/h humans
38 balb/c mice platforms attenuated recombinant l. casei intranasal immunization foreign antigen clades baculoviruses F1 VEEV JJA dengue virus sars-cov spike raav6 S1
39 antigen-specific discussed respiratory syndrome virus food-grade dendritic cell ad vectors m2e-specific plant-based E7 protected hydrogel mature senescent hpiv3/ebogp spike protein
40 balb/c system mtb wcl lactococcus lactis mucosally autologous challenge protein yersinia salivary 4 modified pcdnam ORFV-PEDV-S self-assembling protein
41 t-cell vaccination titers expression immunity competent strains vac-ha-dual G2 ZEBOV volvulus zika virus RVV-S infant rubella
42 CD8 traditional significantly verified mucosal sites SIV protection self-assemble tcov MARV JJAV tick-borne MVA-S EBV receptor binding domain
43 found synthetic viral shedding suckling m.tb viral vector pandemics p17/p24 EP A12-LLV2 adjuvant activity CNS pcdnasb neonates rntd
44 doses made CVCVA5 EGFP ASC hexon influenza a rhdv-vlps sequence leishmania randomized scarification purified nasal secretions ctxb
45 ifn-γ understanding protection COE powder rmv ll-ha1/l/acma subviral expression vectors hev VIT MVTT RBD anti-rsv mers coronavirus
46 vaccines chapter groups fusion resident hiv-1-specific pseudotypes vac-ha antitumor ALA participants tetravalent QS21 infection binding
47 th1 developed vaccine surface NEI CEA HSP65 baculovirus expression system yscf MVA-VP2 charged mva-vectored sars-associated rsv-specific rgp
48 CTL applications np-kag strains T(RM expression influenza virus infection viral genome gun FMD admixed lethal NC intranasal mers‐cov
49 RESULTS include nano-kag groel vaccine delivery system p72 emergent ER integration gp-specific hcv vaccine envelope PIKA natural decoy epitope
50 virus advances infectious bronchitis PPV nasal mucosa adv CHO corn dna-based expressing h7n9 monovalent protection rdis SAS PA20